Anti-PD-1/PD-L1 antibodies are representative immune checkpoint inhibitors widely used in cancer therapies.526,527 These agents act by blocking the PD-1/PD-L1 interaction, thereby releasing the brakes on the immune system and combating cancer immune evasion. The gene discussed is CD274; the disease is cancer.